Evolve Private Wealth LLC Takes $1.86 Million Position in Illumina, Inc. $ILMN

Key Points

• Evolve Private Wealth acquired a new $1.86 million Illumina stake, purchasing 10,602 shares in the second quarter. Institutional investors collectively own approximately 89.4% of ILMN.
• Illumina reported better-than-expected quarterly results, with EPS of $1.31 and revenue of $1.16 billion; revenue rose 9.4% year over year, and fiscal 2026 EPS guidance remains $5.30–$5.40.
• Despite strong results and recent institutional buying, analyst sentiment is mixed, with a consensus “Hold” rating and average price target of $188.40. Heavy insider selling, including substantial sales by director Keith A. Meister, adds a cautionary signal.

Evolve Private Wealth LLC bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,602 shares of the life sciences company's stock, valued at approximately $1,864,000.

Several other hedge funds have also recently modified their holdings of the stock. Empowered Funds LLC lifted its stake in Illumina by 113.7% in the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company's stock valued at $737,000 after buying an additional 4,940 shares in the last quarter. Sivia Capital Partners LLC purchased a new stake in Illumina during the 2nd quarter worth approximately $621,000. CW Advisors LLC purchased a new stake in Illumina during the 2nd quarter worth approximately $275,000. Marshall Wace LLP increased its stake in Illumina by 49.0% during the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company's stock worth $5,691,000 after buying an additional 19,618 shares in the last quarter. Finally, Cresset Asset Management LLC raised its holdings in shares of Illumina by 30.9% during the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company's stock valued at $706,000 after acquiring an additional 1,748 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Stock Up 2.9%

ILMN stock opened at $219.40 on Friday. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The firm has a 50-day moving average of $188.01 and a two-hundred day moving average of $152.44. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $220.43. The company has a market cap of $33.13 billion, a price-to-earnings ratio of 40.93, a PEG ratio of 3.09 and a beta of 1.45.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Illumina news, CAO Scott D. Ericksen sold 1,500 shares of the company's stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total value of $225,150.00. Following the completion of the sale, the chief accounting officer directly owned 14,946 shares in the company, valued at $2,243,394.60. This represents a 9.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of the firm's stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director directly owned 2,372,694 shares of the company's stock, valued at $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 2,095,958 shares of company stock worth $401,720,974. 2.90% of the stock is owned by corporate insiders.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information
• Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation.
• Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina
• Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing
• Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert

Analyst Ratings Changes

Several research firms have recently weighed in on ILMN. Deutsche Bank Aktiengesellschaft downgraded Illumina to a "hold" rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded Illumina from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday, June 3rd. Zacks Research raised Illumina from a "hold" rating to a "strong-buy" rating in a research note on Monday, August 3rd. Canaccord Genuity Group raised their price objective on Illumina from $190.00 to $205.00 and gave the company a "hold" rating in a report on Monday, August 3rd. Finally, Daiwa Securities Group raised shares of Illumina from a "neutral" rating to an "outperform" rating and set a $155.00 target price on the stock in a research note on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Illumina has an average rating of "Hold" and an average target price of $188.40.

Illumina Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source